Navigation Links
Stem Cell Study Shows Benefits in Treatment of Spinal Injuries
Date:11/10/2010

Stem Cell Study Shows Benefits in Treatment of Spinal Injuries -- SEOUL, South Korea, November 10, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

Stem Cell Study Shows Benefits in Treatment of Spinal Injuries

   

Results of 108 Patients Demonstrate Safety and Efficacy

SEOUL, South Korea, November 10, 2010 /PRNewswire/ -- Dr. Geeta Shroff, founder & medical director of Nutech Mediworld, presented today the summary results of a retrospective clinical study of human embryonic stem cell (hESC) therapy in patients with chronic spinal cord injury (SCI). Speaking at the 2nd Annual World Stem Cells & Regenerative Medicine Congress Asia 2010, Dr. Shroff explained her treatment protocol and clinical results, demonstrating the safety and efficacy of her human embryonic stem cell (hESC) therapy. The groundbreaking study was conducted on 108 chronic SCI patients treated by Dr. Shroff over a 6 year period-2004 to 2009. Dr Geeta Shroff also shared her vision, which is to see hESC therapy available globally as the first line of treatment for many of mankind's worst afflictions and her willingness to collaborate with entities and work with regulatory authorities worldwide, to realise this vision.

About the hESC Technology

Dr. Geeta Shroff has developed a commercially viable technology to isolate hESC, culture them, prepare them for clinical application and store them in ready-to-use form with a shelf life of six months. This technology, which has patents applied for worldwide, provides a safe and effective, 'purely human' product, for the treatment of a wide range of medical conditions. The ready-to-use product is universally acceptable as it does not require any cross- matching and has a shelf life of 6 months, making it amenable to global marketing. The technology is being used clinically to treat many conditions including spinal injuries, multiple sclerosis, Parkinson's disease, diabetes, Lyme disease, cerebral palsy and autism. Since 2002, more than 800 patients from 35 countries have been treated at Nutech Mediworld, New Delhi and the number is steadily growing.

For further information, please contact: Nutech Mediworld info@ntmw.net
'/>"/>

SOURCE Nutech Mediworld
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Study Shows Cardiovascular Deaths in Europe Could Be Prevented
2. Week-24 Interim Results From Phase 2b PILLAR Study to be Presented as Late-Breaker at AASLD
3. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
4. Arizona State University awarded $6.5 million to study nanotechnology and society
5. Molecular Detections Detect-Ready™ MRSA Assay Demonstrates Strong Performance In Independent Comparative Study From Leading UK Hospital
6. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
7. Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
8. CoreLab Partners Completes First TQT Study in Japan
9. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
10. ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
11. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Non-profit Consortium Aims to Generate Genomic ... Research and Discovery --> --> ... plan to sequence 100,000 individuals. It is intended to initially ... 7 of North and East Asian countries. ... project will focus on creating phased reference genomes for all ...
(Date:2/11/2016)... Germany and GERMANTOWN, ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... RNA Panels for gene expression profiling, expanding QIAGEN,s portfolio ... The panels enable researchers to select from over 20,000 ... and discover interactions between genes, cellular phenotypes and disease ...
(Date:2/11/2016)... , Feb. 11, 2016  Wellcentive today ... Portland, Oregon -based community care ... provide population health analytics, quality reporting and care ... FamilyCare strengthen its team of quality managers, analysts ... to the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
Breaking Biology Technology:
(Date:1/25/2016)... SEATTLE , Jan. 25, 2016  Glencoe Software, ... biotech, pharma and publication industries, will provide the data ... Phenotypic Screening Centre (NPSC). ... Phenotypic analysis ... even whole organisms, allowing comparisons between states such as ...
(Date:1/22/2016)... , Jan. 22, 2016 ... the addition of the "Global Biometrics ... to their offering. --> ... the "Global Biometrics Market in Retail ... --> Research and Markets ...
(Date:1/20/2016)... , Jan. 20, 2016 A market that ... directly benefit from the explosion in genomics knowledge. Learn ... Sound Research. A range of dynamic trends are pushing ... - personalized medicine - pharmacogenomics - pathogen evolution - ... large markets - greater understanding of the role of ...
Breaking Biology News(10 mins):